Paper Details

  1. Home
  2. Paper Details

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.

Author: BryantAndrew, CameronAlison, GrayEmma, LawrieTheresa A, MorrisonJo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Ovarian cancer is a common cancer in women. This study will review the use of pegylated liposomal doxorubicin (PLD) in the treatment of relapsed epithelial ovarian cancer (EOC).
Paper Details　
Original Abstract of the Article :
Ovarian cancer is the eighth most common cancer in women and it is usually diagnosed at an advanced stage. The majority of ovarian tumours are epithelial in origin. Women with relapsed epithelial ovarian cancer (EOC) often have a reduced performance status with a limited life expectancy, therefore m...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457816/

データ提供：米国国立医学図書館（NLM）

Pegylated Liposomal Doxorubicin for Relapsed Epithelial Ovarian Cancer

The field of [oncology] is constantly seeking new and effective treatments for [ovarian cancer], a challenging disease with a high rate of relapse. This article discusses the use of pegylated liposomal doxorubicin (PLD) for relapsed epithelial ovarian cancer (EOC). The authors provide a comprehensive overview of the treatment landscape for relapsed EOC, highlighting the importance of maintaining quality of life for patients with limited life expectancy. They discuss the role of platinum-based therapy for platinum-sensitive disease and non-platinum drugs for platinum-resistant disease. The article explores the use of PLD as a single-agent treatment or in combination with other therapies, emphasizing its potential benefits and limitations.

Pegylated Liposomal Doxorubicin: A Promising Option for Relapsed Ovarian Cancer

This article offers valuable insights into the use of PLD for relapsed epithelial ovarian cancer. The authors emphasize its potential benefits and limitations, highlighting its role in maintaining quality of life for patients with limited life expectancy.

Improving Treatment Outcomes for Relapsed Ovarian Cancer

As an explorer of the vast and often challenging landscape of oncology, I am always impressed by the dedication of researchers in seeking new and effective therapies. This article highlights the ongoing efforts to improve treatment outcomes for patients with relapsed ovarian cancer. The authors' insights underscore the importance of personalized treatment strategies, considering individual patient factors and the specific needs of those with limited life expectancy.

Dr.Camel's Conclusion

This article provides a comprehensive overview of the use of pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. The authors discuss its potential benefits and limitations, highlighting its role in maintaining quality of life for patients with limited life expectancy.

Date :
  1. Date Completed 2013-12-20
  2. Date Revised 2023-07-10
Further Info :

Pubmed ID

23835762

DOI: Digital Object Identifier

PMC6457816

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.